Activist firm Ananym Capital Management disclosed a sizeable holding in Bio-Techne Corp., a developer of life‑science tools and diagnostic reagents. The hedge fund wrote to the board urging a comprehensive strategic review that weighs all options, including a possible sale. Investors see the move as a signal that the company may be undervalued relative to peers, and could reshape its growth trajectory.

Bio‑Techne’s market cap hovers near $5 billion, giving it a scale that could attract interest from larger pharmaceutical conglomerates or private‑equity sponsors. A sale could unlock value for shareholders but also disrupt ongoing R&D pipelines and customer contracts. Ananym’s push follows a broader activist trend targeting mid‑cap biotech firms with fragmented product portfolios, and may trigger a bidding war among suitors.

Board members now face pressure to commission an independent valuation and outline a timeline for any potential transaction. Creditors and suppliers will monitor the process closely, as a sale could alter payment terms and service agreements. Stakeholders will weigh the cost of integration. The coming weeks will reveal whether Ananym’s campaign forces Bio‑Techne into a formal sale process or a strategic partnership.